Leslie Kam
Overview
Explore the profile of Leslie Kam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramrakhiani H, Le M, Kam L, Nguyen B, Yeo Y, Levesley C, et al.
J Viral Hepat
. 2025 Jan;
32(2):e70003.
PMID: 39831733
Using a systematic review and meta-analytic approach, this study determined the durability of HBV immunity and the prevalence of anamnestic response to a booster HBV vaccine dose in individuals previously...
2.
Rouillard N, Barnett S, Zhang X, Kam L, Manikat R, Cheung R, et al.
Clin Mol Hepatol
. 2024 Nov;
31(1):227-239.
PMID: 39541951
Background/aims: With the obesity pandemic, metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease and a leading cause of end-stage liver disease and liver-related deaths in the...
3.
Becerra A, Kam L, Kim Y, Park H
Am J Health Syst Pharm
. 2024 Oct;
82(6):317-340.
PMID: 39441999
Purpose: This study aimed to identify research publications that have significantly influenced clinical practice in pharmacy using a novel metric known as the disruption score. Methods: We conducted a bibliometric...
4.
Mao X, Zhang X, Kam L, Chien N, Lai R, Cheung K, et al.
Gut
. 2024 Aug;
73(12):2054-2061.
PMID: 39122360
Objective: Type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease (diabetic MASLD) frequently coexist and worsen liver and non-liver outcomes, but effective pharmacological therapies are limited. We aimed to...
5.
Tran S, Zou B, Lee K, Kam L, Yeo Y, Henry L, et al.
Aliment Pharmacol Ther
. 2024 May;
60(2):212-223.
PMID: 38693757
Background: Adverse outcomes of cirrhosis remain a top priority. Aims: We examined the distribution of cirrhosis causes, HCC incidence and mortality and related changes over time in a nationwide U.S....
6.
Tran S, Zou B, Kam L, Lee K, Huang D, Henry L, et al.
J Hepatocell Carcinoma
. 2023 Dec;
10:2147-2158.
PMID: 38076642
Background & Aim: Causes of hepatocellular carcinoma (HCC) may change as treatments become available for some liver diseases. We examined the distribution of HCC cause and survival of a nationwide...
7.
Ogawa E, Chien N, Kam L, Yeo Y, Ji F, Huang D, et al.
JAMA Intern Med
. 2022 Dec;
183(2):97-105.
PMID: 36508196
Importance: Chronic hepatitis C (CHC) and its complications are associated with high rates of morbidity and mortality. However, large-scale data analysis of the long-term liver and nonliver effects of direct-acting...
8.
Nguyen V, Kam L, Yeo Y, Huang D, Henry L, Cheung R, et al.
JAMA Netw Open
. 2022 Dec;
5(12):e2245424.
PMID: 36477481
Importance: Clinical data on hepatitis C virus (HCV) treatment rates in the United States are sparse. Objective: To evaluate HCV treatment rates in the era of direct-acting antivirals (DAAs). Design,...
9.
Chang C, Kam L, Dang N, Cheung R, Nguyen M
Dig Dis
. 2021 Aug;
40(4):497-505.
PMID: 34348281
Introduction: Treatment criteria for chronic hepatitis B (CHB) relies on ALT, which can be impacted by concurrent nonalcoholic fatty liver disease (NAFLD), but ALT data on patients with CHB and...
10.
Huang C, Iio E, Won Jun D, Ogawa E, Toyoda H, Hsu Y, et al.
Hepatol Int
. 2019 Aug;
13(5):587-598.
PMID: 31463665
Background And Aims: One-third of the global hepatitis C virus (HCV) burden is found in Asia. Real-world data from diverse East Asian cohorts remain limited. This study addressed the real-world...